MedTrace Logo

Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

NCT06054698 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2026-05-22

No results posted yet for this study

Summary

To assess the efficacy of HRS9531 injection compared with placebo in weight reduction in overweight or obese subjects after 36 weeks of treatment.

Conditions

  • Overweight or Obesity

Interventions

DRUG

HRS9531 injection

HRS9531 injection , QW，36 weeks

DRUG

HRS9531 injection Placebo

HRS9531 injection Placebo，QW，36 weeks

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-16
Primary Completion
2024-09-09
Completion
2024-09-09

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06054698 on ClinicalTrials.gov